drugset / Trial / NCT00192140
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
Non-randomizedSingle-groupOpen-labelTreatment
Summary
* To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. * To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age. * To describe the genotypic and phenotypic stability of shed vaccine viruses. * To describe the immune responses of FluMist in individuals 5-49 years of age. * To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response
Timeline
- Start
- 2004-06
- Primary completion
- 2004-10
- Completion
- 2005-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | FluMist | Vaccine | — | Intranasal |